© 2022 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
A triple regimen of Opdivo, Yervoy and Cabometyx showed good activity, but side effects may limit its use.
Those with fatty liver disease and cirrhosis should undergo regular screening.
TRK inhibitor larotrectinib led to durable responses in people with colon, pancreatic, appendix, bile duct and liver cancers.
Tecentriq plus Avastin improved improved overall survival and patient experiences during treatment.
Many people with GI cancers are diagnosed only after the disease has spread through the body, so this test could aid in early detection.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
